Using Artificial Intelligence for the Detection of Respiratory Diseases Associated With Pollution

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

30000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Generating a picture at the city level, through geospatial and temporal grouping a lung diseases associated or exacerbated by pollution (COPD, AB and neoplasm pulmonary or pleural) and correlating this data with pollution data.

Development of an accurate and prognostic HRCT imaging diagnostic tool, computer assisted in the mentioned pathology, by generating an algorithm capable of to detect early the follow-up tomographic imaging lesions, as well as to evaluate objective their speed of evolution.

Validation of the proposed algorithm by comparison with medical diagnosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of an Artificial Intelligence Enabled Diagnostic Support Software (ArtiQ.Spiro) in Primary Care Spirometry Datasets - a Retrospective Analysis

NCT05648227

Respiratory Disease

ACTIVE_NOT_RECRUITING

Artificial Intelligence in Computed Tomography for Quantifying Lung Changes of Bronchiectasis Patients

NCT05751538

Bronchiectasis

UNKNOWN

Real Time Early Warning Model and Mobile Medical Assistant System for the Impact of Air Pollution on AECOPD Disease

NCT04960410

COPD

COMPLETED

Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis

NCT01906047

Bronchiectasis

COMPLETED

USE OF ARTIFICIAL INTELLIGENCE IN A PULMONARY FIBROSIS CLINIC

NCT06852794

Interstitial Disease

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Asthma Lung Neoplasm Emphysema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must be diagnosed with COPD and/or asthma and/or pulmonary neoplasm and/or secondary pulmonary, pleural or mediastinal determinations, suspected or confirmed, according to ICD-10.
* Patients will be included regardless of the type of hospitalization, continuous or day.
* The existence of freely expressed consent, carried out according to Ethics standards professional (from the observation sheet).

For stage 2

* The use of HRCT images, in DICOM format, with a maximum cup thickness of 1.5 mm and with an average of 250 cups; no image acquisition errors;
* Imaging monitoring at a time interval;.
* Respiratory function evaluation data available: spirometry +/- the factor of gaseous diffusion (DLco);

Exclusion Criteria

For both stages:

\- Patients who do not have a stable real domicile (eg social cases) or are not from the Timis county

For stage 2

* Patients who do not have HRCT images available or cannot be followed.
* Patients who have insufficient quality HRCT images.
* Patients who have a history of lung surgery.
* Patients who have a history of allergies to contrast agents used in imaging HRCT.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No